Challenge. A mid-sized pharma group acquiring a target across two jurisdictions faced a high effective tax rate and FEMA reporting complexity on the holding structure.
Approach. We modelled alternative holding chains, applied the relevant treaty network, validated substance and beneficial-ownership conditions, and aligned the FEMA filings (FC-GPR/ODI) with the deal timeline.
Outcome. The implemented structure reduced the group's effective tax rate by approximately 8% on the acquired earnings stream, with all cross-border filings completed on time.
Illustrative and anonymised. No client is identified. Outcomes depend on facts and are not a guarantee of results.
